Overview
ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that provides neuroprotective effects without stimulating red blood cell production. Originally developed for treating neuropathic pain and diabetic complications, this peptide has shown promise in protecting and repairing nerve tissue.
Unlike EPO, ARA-290 selectively activates tissue-protective receptors while avoiding hematopoietic effects. This selectivity makes it valuable for neurological applications without the risks associated with increased red blood cell count.
How It Works
- Tissue-protective receptor activation: Stimulates repair pathways without hematopoietic effects
- Neuroprotection: Protects nerve cells from damage and promotes regeneration
- Anti-inflammatory action: Reduces neuroinflammation
- Metabolic support: Improves cellular energy metabolism in nerves
- Angiogenesis: Promotes formation of new blood vessels in damaged tissues
Benefits
- Neuropathic pain relief: Reduction in nerve-related pain
- Diabetic neuropathy: Potential benefits for diabetic nerve damage
- Nerve regeneration: Support for healing damaged nerves
- Tissue protection: General cytoprotective effects
- Improved circulation: Enhanced blood flow to damaged areas
- Reduced inflammation: Anti-inflammatory effects in tissues
Research Protocol
- Typical research dose: 2-4 mg daily
- Administration: Subcutaneous injection
- Duration: 4-12 weeks in studies
- Note: Investigational compound only